What is the current valuation of the Opioid Withdrawal Treatment Market?

As of 2024, the market valuation was 3.218 USD Billion. Read More

What is the projected market size for the Opioid Withdrawal Treatment Market by 2035?

The market is projected to reach 5.59 USD Billion by 2035. Read More

What is the expected CAGR for the Opioid Withdrawal Treatment Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 5.15%. Read More

What were the segment valuations for medications in the Opioid Withdrawal Treatment Market in 2024?

In 2024, the segment valuation for medications was 1.5 USD Billion, projected to grow to 2.5 USD Billion. Read More

How does the route of administration impact the Opioid Withdrawal Treatment Market?

The market segments by route of administration include oral, injectable, transdermal, and nasal, with oral valued at 1.5 USD Billion in 2024. Read More

What are the patient types considered in the Opioid Withdrawal Treatment Market?

The market categorizes patients into inpatient, outpatient, and emergency types, with inpatient valued at 1.5 USD Billion in 2024. Read More

What age groups are targeted in the Opioid Withdrawal Treatment Market?

The market segments age groups into children, adolescents, adults, and the elderly, with adults valued at 2.0 USD Billion in 2024. Read More

Who are the key players in the Opioid Withdrawal Treatment Market?

Key players include Indivior PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., and Purdue Pharma L.P. Read More

What trends are influencing the growth of the Opioid Withdrawal Treatment Market?

Trends include increasing awareness of opioid addiction and the development of innovative treatment options, contributing to market growth. Read More

Opioid Withdrawal Treatment Market

Q: Which treatment types are included in the Opioid Withdrawal Treatment Market?

The market includes medications, therapeutic procedures, psychological counseling, and support groups. Read More

ID: MRFR/HC/6651-HCR

90 Pages

Nidhi Mandole

Last Updated: May 15, 2026

Opioid Withdrawal Treatment Market Research Report By Treatment Type (Medications, Therapeutic Procedures, Psychological Counseling, Support Groups), By Route of Administration (Oral, Injectable, Transdermal, Nasal), By Patient Type (Inpatient, Outpatient, Emergency), By Age Group (Children, Adolescents, Adults, Elderly) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Treatment Type (USD Billion) | |
  1. 4.1.1 Medications | |
  2. 4.1.2 Therapeutic Procedures | |
  3. 4.1.3 Psychological Counseling | |
  4. 4.1.4 Support Groups |
2. 4.2 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.2.1 Oral | |
  2. 4.2.2 Injectable | |
  3. 4.2.3 Transdermal | |
  4. 4.2.4 Nasal |
3. 4.3 Healthcare, BY Patient Type (USD Billion) | |
  1. 4.3.1 Inpatient | |
  2. 4.3.2 Outpatient | |
  3. 4.3.3 Emergency |
4. 4.4 Healthcare, BY Age Group (USD Billion) | |
  1. 4.4.1 Children | |
  2. 4.4.2 Adolescents | |
  3. 4.4.3 Adults | |
  4. 4.4.4 Elderly |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Indivior PLC (GB) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Mylan N.V. (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Teva Pharmaceutical Industries Ltd. (IL) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Alkermes PLC (IE) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Purdue Pharma L.P. (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Horizon Therapeutics PLC (IE) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Camurus AB (SE) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 NantKwest Inc. (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Sorrento Therapeutics Inc. (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE |
7. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
8. 6.5 US MARKET ANALYSIS BY PATIENT TYPE |
9. 6.6 US MARKET ANALYSIS BY AGE GROUP |
10. 6.7 CANADA MARKET ANALYSIS BY TREATMENT TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
12. 6.9 CANADA MARKET ANALYSIS BY PATIENT TYPE |
13. 6.10 CANADA MARKET ANALYSIS BY AGE GROUP |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
17. 6.14 GERMANY MARKET ANALYSIS BY PATIENT TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY AGE GROUP |
19. 6.16 UK MARKET ANALYSIS BY TREATMENT TYPE |
20. 6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
21. 6.18 UK MARKET ANALYSIS BY PATIENT TYPE |
22. 6.19 UK MARKET ANALYSIS BY AGE GROUP |
23. 6.20 FRANCE MARKET ANALYSIS BY TREATMENT TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
25. 6.22 FRANCE MARKET ANALYSIS BY PATIENT TYPE |
26. 6.23 FRANCE MARKET ANALYSIS BY AGE GROUP |
27. 6.24 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
29. 6.26 RUSSIA MARKET ANALYSIS BY PATIENT TYPE |
30. 6.27 RUSSIA MARKET ANALYSIS BY AGE GROUP |
31. 6.28 ITALY MARKET ANALYSIS BY TREATMENT TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
33. 6.30 ITALY MARKET ANALYSIS BY PATIENT TYPE |
34. 6.31 ITALY MARKET ANALYSIS BY AGE GROUP |
35. 6.32 SPAIN MARKET ANALYSIS BY TREATMENT TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
37. 6.34 SPAIN MARKET ANALYSIS BY PATIENT TYPE |
38. 6.35 SPAIN MARKET ANALYSIS BY AGE GROUP |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TREATMENT TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
46. 6.43 CHINA MARKET ANALYSIS BY PATIENT TYPE |
47. 6.44 CHINA MARKET ANALYSIS BY AGE GROUP |
48. 6.45 INDIA MARKET ANALYSIS BY TREATMENT TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
50. 6.47 INDIA MARKET ANALYSIS BY PATIENT TYPE |
51. 6.48 INDIA MARKET ANALYSIS BY AGE GROUP |
52. 6.49 JAPAN MARKET ANALYSIS BY TREATMENT TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
54. 6.51 JAPAN MARKET ANALYSIS BY PATIENT TYPE |
55. 6.52 JAPAN MARKET ANALYSIS BY AGE GROUP |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
62. 6.59 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY AGE GROUP |
64. 6.61 THAILAND MARKET ANALYSIS BY TREATMENT TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
66. 6.63 THAILAND MARKET ANALYSIS BY PATIENT TYPE |
67. 6.64 THAILAND MARKET ANALYSIS BY AGE GROUP |
68. 6.65 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
70. 6.67 INDONESIA MARKET ANALYSIS BY PATIENT TYPE |
71. 6.68 INDONESIA MARKET ANALYSIS BY AGE GROUP |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
74. 6.71 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY AGE GROUP |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
79. 6.76 BRAZIL MARKET ANALYSIS BY PATIENT TYPE |
80. 6.77 BRAZIL MARKET ANALYSIS BY AGE GROUP |
81. 6.78 MEXICO MARKET ANALYSIS BY TREATMENT TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
83. 6.80 MEXICO MARKET ANALYSIS BY PATIENT TYPE |
84. 6.81 MEXICO MARKET ANALYSIS BY AGE GROUP |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
87. 6.84 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY AGE GROUP |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
104. 6.101 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY AGE GROUP |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY AGE GROUP, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY AGE GROUP, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY AGE GROUP, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY AGE GROUP, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY AGE GROUP, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY AGE GROUP, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY AGE GROUP, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY AGE GROUP, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY AGE GROUP, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY AGE GROUP, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY AGE GROUP, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY AGE GROUP, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY AGE GROUP, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY AGE GROUP, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY AGE GROUP, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY AGE GROUP, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY AGE GROUP, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY AGE GROUP, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY AGE GROUP, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY AGE GROUP, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY AGE GROUP, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY AGE GROUP, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY AGE GROUP, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY AGE GROUP, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY AGE GROUP, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY AGE GROUP, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY AGE GROUP, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY AGE GROUP, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY AGE GROUP, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Opioid Withdrawal Treatment Market Segmentation

Opioid Withdrawal Treatment Market By Treatment Type (USD Billion, 2025-2035)

Medications
Therapeutic Procedures
Psychological Counseling
Support Groups

Opioid Withdrawal Treatment Market By Route of Administration (USD Billion, 2025-2035)

Oral
Injectable
Transdermal
Nasal

Opioid Withdrawal Treatment Market By Patient Type (USD Billion, 2025-2035)

Inpatient
Outpatient
Emergency

Opioid Withdrawal Treatment Market By Age Group (USD Billion, 2025-2035)

Children
Adolescents
Adults
Elderly

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”